Research on New Drugs and Drug Targets in Melanoma

Dear Colleagues,

The incidence of melanoma is steadily increasing worldwide. Malignant melanomas are dangerous skin cancers, and their treatment with various cytostatics often causes side effects; moreover, their prolonged use can lead to drug resistance. Surgical excision is the main method of treatment, and in the case of metastasis or resistance, other methods of treatment are available. Understanding the mechanisms and cellular pathways of melanoma allows for the development of more effective therapies, including immune checkpoint inhibitors, targeted therapies based on signaling pathways, intrafocal therapy (for unremovable melanomas) and local therapy (for single melanomas). The treatment of metastatic or drug-resistant melanoma still represents a significant therapeutic challenge. In recent years, new drugs have been introduced to treat melanoma, but scientists are still looking for new treatment options to improve therapeutic outcomes and increase patient survival.
The purpose of this Special Issue is to present new drugs or substances with potential against melanoma. Additionally, we are interested in drug targets and their mechanisms of action on many levels, including molecular and cellular.

Dr. Paula Wróblewska Łuczka
Dr. Nicolas Dumaz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• melanoma
• new drugs
• drug targets
• mechanism of action
• substances with anti-melanoma potential